Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib in Recurrent or Metastatic Adenoid Cystic Carcinoma
NCT07682675Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Apr 2029
- Countries
- 1
- Sponsor
- Unicancer
- Drugs
- zanzalintinib
- Conditions
- adenoid cystic carcinoma (ACC)
01
Overview
Phase 2, open-label, single-arm trial of zanzalintinib in adenoid cystic carcinoma (ACC), sponsored by Unicancer. Primary endpoint: Objective Response Rate at 12 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Experimental arm
Zanzalintinib per os 60mg daily
03
Who it enrols
Adults with recurrent/metastatic adenoid cystic carcinoma of the head and neck, measurable disease, recent progression, and ECOG PS 0-1. Excludes prior VEGFR inhibitors, active brain metastases, and significant cardiovascular or GI disorders.
04
Endpoints
Primary
Objective Response Rate
Beyond the preview
Go deeper on NCT07682675.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07682675.